Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway

Genes and Development

Volumn 24, Issue 6, 2010, Pages 549-560

  Wilhelm, Margareta T ^a,b   Rufini, Alessandro ^a,c   Wetzel, Monica K ^d   Tsuchihara, Katsuya ^a,e   Inoue, Satoshi ^a   Tomasini, Richard ^a,f   Itie Youten, Annick ^a   Wakeham, Andrew ^a   Arsenian Henriksson, Marie ^b   Melino, Gerry ^c,g   Kaplan, David R ^d,h   Miller, Freda D ^d,h   Mak, Tak W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f INSERM   (France)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; DNA damage response; Neurodegeneration; p53; p73

Indexed keywords

ATM PROTEIN; BINDING PROTEIN; PROTEIN DELTA NP73; PROTEIN P53; PROTEIN P53 BINDING PROTEIN 1; PROTEIN P73; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA STRAND BREAKAGE; EMBRYO; FERTILITY; GENE FUNCTION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BRAIN; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; FERTILITY; GENE EXPRESSION REGULATION; HCT116 CELLS; HUMANS; LONGEVITY; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURODEGENERATIVE DISEASES; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 77949362925     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1873910     Document Type: Article

References (47)

1. Armata HL, Garlick DS, Sluss HK. 2007. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res 67: 11696-11703.
2. Ashcroft M, Kubbutat MH, Vousden KH. 1999. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19: 1751-1758.
3. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, et al. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
4. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870.
5. Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H, Bretz AC, Burek C, Rosenwald A, Stiewe T. 2008. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J 27: 792-803.
6. Campisi J, d'Adda di Fagagna F. 2007. Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740.
7. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679.
8. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M. 2002. Expression of δNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251.
9. Collado M, Serrano M. 2010. Senescence in tumours: Evidence from mice and humans. Nat Rev Cancer 10: 51-57.
10. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, et al. 2005. Tumour biology: Senescence in premalignant tumours. Nature 436: 642.
11. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, et al. 2005. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: Evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 11: 8372-8383.
12. Daniel JA, Pellegrini M, Lee JH, Paull TT, Feigenbaum L, Nussenzweig A. 2008. Multiple autophosphorylation sites are dispensable for murine ATM activation in vivo. J Cell Biol 183: 777-783.
13. Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, Iwabuchi K, Doherty AJ. 2002. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J 21: 3863-3872.
14. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
15. Fu L, Minden MD, Benchimol S. 1996. Translational regulation of human p53 gene expression. EMBO J 15: 4392-4401.
16. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, et al. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913.
17. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, et al. 2001. Human DNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8: 1213-1223.
18. Halazonetis TD, Gorgoulis VG, Bartek J. 2008. An oncogene-induced DNA damage model for cancer development. Science 319: 1352-1355.
19. Liu G, Chen X. 2005. The C-terminal sterile a motif and the extreme C terminus regulate the transcriptional activity of the a isoform of p73. J Biol Chem 280: 20111-20119.
20. Liu X, Yue P, Khuri FR, Sun SY. 2005. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 65: 9169-9175.
21. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY. 2006. Expression of δNp73 and TAp73α independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 12: 3922-3927.
22. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V. 2004. DNA damage induces the rapid and selective degradation of the δNp73 isoform, allowing apoptosis to occur. Cell Death Differ 11: 685-687.
23. Melino G, De Laurenzi V, Vousden KH. 2002. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615.
24. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, et al. 2005. TAp73/Δ Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12: 1564-1577.
25. Pellegrini M, Celeste A, Difilippantonio S, Guo R, Wang W, Feigenbaum L, Nussenzweig A. 2006. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. Nature 443: 222-225.
26. Petrenko O, Zaika A, Moll UM. 2003. ΔNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 23: 5540-5555.
27. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. 2000. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289: 304-306.
28. Pozniak CD, Barnabe-Heider F, Rymar VV, Lee AF, Sadikot AF, Miller FD. 2002. p73 is required for survival and maintenance of CNS neurons. J Neurosci 22: 9800-9809.
29. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ Jr, Appella E, Anderson CW. 2003. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278: 37536-37544.
30. Sayan AE, Paradisi A, Vojtesek B, Knight RA, Melino G, Candi E. 2005. New antibodies recognizing p73: Comparison with commercial antibodies. Biochem Biophys Res Commun 330:186-193.
31. Sluss HK, Armata H, Gallant J, Jones SN. 2004. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 24: 976-984.
32. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. 2002. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res 62: 3598-3602.
33. Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Putzer BM. 2003. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. J Biol Chem 278: 14230-14236.
34. Tissir F, Ravni A, Achouri Y, Riethmacher D, Meyer G, Goffinet AM. 2009. DNp73 regulates neuronal survival in vivo. Proc Natl Acad Sci 106: 16871-16876.
35. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, et al. 2008. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes & Dev 22: 2677-2691.
36. Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A, Tsao MS, Iovanna JL, Jurisicova A, Melino G, et al. 2009. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci 106: 797-802.
37. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K, Yasumoto K. 2004. Expression of ΔNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911.
38. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
39. Ward IM, Minn K, van Deursen J, Chen J. 2003. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol 23: 2556-2563.
40. Webster GA, Perkins ND. 1999. Transcriptional cross talk between NF-κB and p53. Mol Cell Biol 19: 3485-3495.
41. Wetzel MK, Naska S, Laliberte CL, Rymar VV, Fujitani M, Biernaskie JA, Cole CJ, Lerch JP, Spring S, Wang SH, et al. 2008. p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer's disease. Neuron 59: 708-721.
42. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
43. Yang A, Schweitzer R, Sun D, Kaghad M,Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, et al. 1999. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
44. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, et al. 2000. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404: 99-103.
45. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. 2002. ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196: 765-780.
46. Zgheib O, Huyen Y, DiTullio RA Jr, Snyder A, Venere M, Stavridi ES, Halazonetis TD. 2005. ATM signaling and 53BP1. Radiother Oncol 76: 119-122.
47. Zitterbart K, Zavrelova I, Kadlecova J, Spesna R, Kratochvilova A, Pavelka Z, Sterba J. 2007. p73 expression in medulloblastoma: TAp73/ΔNp73 transcript detection and possible association of p73α/ΔNp73 immunoreactivity with survival. Acta Neuropathol 114: 641-650.